Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system

Experimental Cell Research

Volumn 318, Issue 13, 2012, Pages 1577-1585

  Karlsson, Henning ^a   Fryknäs, Mårten ^a   Larsson, Rolf ^a   Nygren, Peter ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cancer drug; Cell culture; Colon cancer; Monolayer; Spheroid; Tumor cell

Indexed keywords

ACRIFLAVINE; ANTINEOPLASTIC AGENT; FLUORESCEIN DIACETATE; FLUOROURACIL; GREEN FLUORESCENT PROTEIN; IRINOTECAN; MELPHALAN; OXALIPLATIN;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL CULTURE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; HYPOXIA; PHENOTYPE; PRIORITY JOURNAL; SOLID TUMOR;

LONCHOCARPUS GLAUCIFOLIUS;

EID: 84862003156     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.03.026     Document Type: Article

References (36)

1. Colotta F. Anticancer drug discovery and development. Adv. Exp. Med. Biol. 2008, 610:19-42.
2. Schwartsmann G., Ratain M.J., Cragg G.M., Wong J.E., Saijo N., Parkinson D.R., Fujiwara Y., Pazdur R., Newman D.J., Dagher R., Di Leone L. Anticancer drug discovery and development throughout the world. J. Clin. Oncol. 2002, 20:47S-59S.
3. Lindhagen E., Nygren P., Larsson R. The fluorometric microculture cytotoxicity assay. Nat. Protoc. 2008, 3:1364-1369.
4. von Hoff D.D. Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development. Cancer Metastasis Rev. 1988, 7:357-371.
5. Weisenthal L.M., Lippman M.E. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat. Rep. 1985, 69:615-632.
6. Chabner B.A., Roberts T.G. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 2005, 5:65-72.
7. Weisenthal L.M. Antineoplastic drug screening belongs in the laboratory, not in the clinic. J. Natl. Cancer Inst. 1992, 84:466-469.
8. Nygren P., Larsson R. Predictive tests for individualization of pharmacological cancer treatment. Expert Opin. Med. Diagn. 2008, 2:349-360.
9. Yoshii Y., Waki A., Yoshida K., Kakezuka A., Kobayashi M., Namiki H., Kuroda Y., Kiyono Y., Yoshii H., Furukawa T., Asai T., Okazawa H., Gelovani J.G., Fujibayashi Y. The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation. Biomaterials 2011, 32:6052-6058.
10. Kunz-Schughart L.A., Freyer J.P., Hofstaedter F., Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J. Biomol. Screen. 2004, 9:273-285.
11. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
12. Mueller-Klieser W. Multicellular spheroids. A review on cellular aggregates in cancer research. J. Cancer Res. Clin. Oncol. 1987, 113:101-122.
13. Kim J.B., Stein R., O'Hare M.J. Three-dimensional in vitro tissue culture models of breast cancer - a review. Breast Cancer Res. Treat. 2004, 85:281-291.
14. Ravizza R., Molteni R., Gariboldi M.B., Marras E., Perletti G., Monti E. Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. Eur. J. Cancer 2009, 45:890-898.
15. Bukholm I.K., Nesland J.M. Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch. 2000, 436:224-228.
16. Guo W., Giancotti F.G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 2004, 5:816-826.
17. Rego R.L., Foster N.R., Smyrk T.C., Le M., O'Connell M.J., Sargent D.J., Windschitl H., Sinicrope F.A. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br. J. Cancer 2010, 102:165-172.
18. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
19. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15545-15550.
20. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
21. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., Berry S.R., Krahn M., Price T., Simes R.J., Tebbutt N.C., van Hazel G., Wierzbicki R., Langer C., Moore M.J. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 2007, 357:2040-2048.
22. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., Erdkamp F.L., Vos A.H., van Groeningen C.J., Sinnige H.A., Richel D.J., Voest E.E., Dijkstra J.R., Vink-Borger M.E., Antonini N.F., Mol L., van Krieken J.H., Dalesio O., Punt C.J. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:563-572.
23. Hassan S., Laryea D., Mahteme H., Felth J., Fryknas M., Fayad W., Linder S., Rickardson L., Gullbo J., Graf W., Pahlman L., Glimelius B., Larsson R., Nygren P. Novel activity of acriflavine against colorectal cancer tumor cells. Cancer Sci. 2011, 102:2206-2213.
24. Gullbo J., Fryknas M., Rickardson L., Darcy P., Hagg M., Wickstrom M., Hassan S., Westman G., Brnjic S., Nygren P., Linder S., Larsson R. Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment. Biochem. Pharmacol. 2011, 82:139-147.
25. Dhar S., Gullbo J., Nilsson K., Nygren P., Larsson R. A nonclonogenic cytotoxicity assay using primary cultures of patient tumor cells for anticancer drug screening. J. Biomol. Screen. 1998, 3:207-216.
26. Csoka K., Tholander B., Gerdin E., de la Torre M., Larsson R., Nygren P. In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer 1997, 72:1008-1012.
27. Larsson R., Kristensen J., Sandberg C., Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer 1992, 50:177-185.
28. Larsson R., Dhar S., Ehrsson H., Nygren P., Lewensohn R. Comparison of the cytotoxic activity of melphalan with l-prolyl-m-l-sarcolysyl-l-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients. Br. J. Cancer 1998, 78:328-335.
29. Gilman A., Philips F.S. The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science 1946, 103:409-436.
30. Nygren P., Larsson R. Overview of the clinical efficacy of investigational anticancer drugs. J. Intern. Med. 2003, 253:46-75.
31. Tewari K., Manetta A. In vitro chemosensitivity testing and mechanisms of drug resistance. Curr. Oncol. Rep. 1999, 1:77-84.
32. Blumenthal R.D. An overview of chemosensitivity testing. Methods Mol. Med. 2005, 110:3-18.
33. Steff A.M., Fortin M., Arguin C., Hugo P. Detection of a decrease in green fluorescent protein fluorescence for the monitoring of cell death: an assay amenable to high-throughput screening technologies. Cytometry 2001, 45:237-243.
34. Naor D., Nedvetzki S., Golan I., Melnik L., Faitelson Y. CD44 in cancer. Crit. Rev. Clin. Lab. Sci. 2002, 39:527-579.
35. Lin E.H., Hassan M., Li Y., Zhao H., Nooka A., Sorenson E., Xie K., Champlin R., Wu X., Li D. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 2007, 110:534-542.
36. Mimeault M., Batra S.K. Recent advancements on the identification of immature cancer cells with the stem cell-like properties in different aggressive and recurrent cancer types. Anticancer Agents Med. Chem. 2010, 10:103.